Spyre Therapeutics Inc. (SYRE) 12-Month Stock Forecast & Price Target Cone
Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
Drag to Test Your SYRE Position Size: $10,000
Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)
Street Historical Accuracy: 64/100| Wall Street Firm | Stance | 12M Target | 1Y Accuracy | Track Grade |
|---|---|---|---|---|
| Morgan StanleyInstitutional Equity Desk | HOLD | $102 | 74% | A |
| Goldman SachsSector Coverage Lead | UNDERPERFORM | $109 | 69% | B |
| JP MorganUS Large-Cap Research | SELL | $88 | 58% | C |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring SYRE)
- ✓Live walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.
SYRE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is SYRE's 12-month stock price target?
Spyre Therapeutics Inc. (SYRE) carries a 12-month consensus base price target of $98.51 (-0.5% from $98.96), with a bull-case target of $116.24 and a bear-case floor of $76.84.
Is SYRE stock a Buy, Hold, or Sell right now?
Roarable's 5-Pillar RQD Quant Engine rates SYRE D+ (Sell — SELL) with an RQD Confidence score of 57/100.